Hims & Hers Health (HIMS) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's (LLY) weight loss drug, Zepbound, has been resolved. The stock ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 32.39% higher than today’s price of $778.00.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Earnings Report 1.900 USD Q4 2021 Earnings Release 02/03/2022 Indices Commodities Currencies Stocks ...

The FDA confirmed on Thursday that Eli Lilly’s tirzepatide, marketed as Zepbound for weight loss, is no longer in shortage, multiple outlets reported. The agency added that it will give compounders 60 ...

On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...

Mounjaro, a weekly injectable drug by Eli Lilly for treating type 2 diabetes and obesity, competes with another high-profile drug, Ozempic (manufactured by Danish drugmaker, Novo Nordisk) Not just ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is ...